ADVERTISEMENT

Clinical Summary

Type 2 diabetes: meta-analysis identifies harm associated with sulphonylurea use

Miriam Tucker   |   28 October 2022

Takeaway

  • Compared with glucose-lowering drugs for type 2 diabetes (T2D) with lower hypoglycaemic potential, sulphonylureas had higher odds for all-cause mortality (ACM), major adverse cardiovascular events (MACE), myocardial infarction (MI), and hypoglycaemia.
  • Among individual sulphonylureas, glimepiride may be the safest.

Why this matters

  • Sulphonylureas are low in cost and effectively...

          

November Challenge

Ends in 11h
left
right

Topic Challenges

left
right